0000874716-24-000017.txt : 20240209
0000874716-24-000017.hdr.sgml : 20240209
20240209170355
ACCESSION NUMBER: 0000874716-24-000017
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240208
FILED AS OF DATE: 20240209
DATE AS OF CHANGE: 20240209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FENNELL GEORGE
CENTRAL INDEX KEY: 0001521861
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19271
FILM NUMBER: 24615986
MAIL ADDRESS:
STREET 1: ONE IDEXX DRIVE
CITY: WESTBROOK
STATE: ME
ZIP: 04092
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDEXX LABORATORIES INC /DE
CENTRAL INDEX KEY: 0000874716
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 010393723
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE IDEXX DRIVE
CITY: WESTBROOK
STATE: ME
ZIP: 04092-2041
BUSINESS PHONE: 2075560300
MAIL ADDRESS:
STREET 1: ONE IDEXX DRIVE
CITY: WESTBROOK
STATE: ME
ZIP: 04092-2041
FORMER COMPANY:
FORMER CONFORMED NAME: IDEXX CORP / DE
DATE OF NAME CHANGE: 19600201
4
1
wk-form4_1707516212.xml
FORM 4
X0508
4
2024-02-08
0
0000874716
IDEXX LABORATORIES INC /DE
IDXX
0001521861
FENNELL GEORGE
ONE IDEXX DRIVE
WESTBROOK
ME
04092
0
1
0
0
SVP, Chief Revenue Officer
0
Common Stock
2024-02-08
4
M
0
1612
62
A
6712
D
Common Stock
2024-02-08
4
M
0
8198
62
A
14910
D
Common Stock
2024-02-08
4
S
0
1209
572.1356
D
13701
D
Common Stock
2024-02-08
4
S
0
2279
572.7797
D
11422
D
Common Stock
2024-02-08
4
S
0
1125
573.9761
D
10297
D
Common Stock
2024-02-08
4
S
0
3173
575.0167
D
7124
D
Common Stock
2024-02-08
4
S
0
412
575.8027
D
6712
D
Incentive Stock Option (right-to-buy)
62
2024-02-08
4
M
0
1612
0
D
2024-02-13
Common Stock
1612
0
D
Non-Qualified Stock Option (right-to-buy)
62
2024-02-08
4
M
0
8198
0
D
2024-02-13
Common Stock
8198
0
D
Represents the weighted average price of the shares sold ranging from a low of $571.50 to a high of $572.45 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $572.525 to a high of $573.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $573.58 to a high of $574.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $574.625 to a high of $575.39 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Represents the weighted average price of the shares sold ranging from a low of $575.78 to a high of $575.845 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
Grant of option to buy 806 shares of Issuer common stock that vested in one installment on February 14, 2019, without giving effect to a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the 'Stock Split'). The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.
Grant of option to buy 4,099 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2015, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.
/s/ Lily J. Lu, Attorney-in-Fact for George Fennell
2024-02-09